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Abstract 
The isolated rat diaphragm was used as an in vitro model to 
quantitate the effects of insulin on glucose uptake. Experi¬ 
ments were conducted on quarter diaphragms to test the effects 
of in vitro treatments. Using this technique, it was found 
that insulin significantly affected glucose uptake when added 
in vitro at a concentration of 100 uU/ml. The addition of 
-estradiol (2 x 10-3 uM) had no effect on either basal 
or insulin-stimulated uptake. Furthermore, perincubation of 
diaphragm muscle in estradiol (2 uM) followed by incubation 
with estradiol (2 x 10~3 uM) and insulin had no effect on 
glucose uptake. 
In a second set of experiments, animals were injected in vivo 
with sesame oil (Group I) and estradiol in sesame oil (Group II) 
for two weeks. The excised hemidiaphragms were then incubated 
with and without added insulin in vitro. In the basal state, 
estrogen pretreatment was found to reduce glucose uptake by 
16% as compared to control (p<.001). In the presence of 
insulin, pretreatment was associated with a 22% increase in 
glucose uptake when compared to Group I (p<.001). Insulin 
increased the mean glucose uptake above the basal state by 38% 
in control animals and 103% in treated animals. This represents 
a 2 to 3 fold rise in sulin responsiveness after estrogen 
administration. Estradiol treatment was not associated with 
changes in fasting plasma immunoreactive insulin or glucose 
concentrations. 
These findings support previous data that show estrogens to 
have a protective effect on the development of diabetes in 
subtotally pancreatectomized animals. Our experiments suggest 
that the mechanism for this improvement in carbohydrate 
tolerance may be the increased insulin sensitivity of muscle 
following estrogen treatment. Oral contraceptive-induced 
glucose intolerance may be related to the use of synthetic 
agents in combination, especially mestranol with some progestin 
compounds, and may be mediated by an increase in growth hormone 
concentrations. 
Estradiol has been shown to increase the glycogen content of 
certain tissues independent of insulin action. In the rat 
diaphragm, increased insulin sensitivity alone can augment 
glycogen synthesis when animals are treated in vivo. When 
incubated in a medium containing glucose but no insulin, the 
treated muscle is expected to take up less glucose to supply 
substrate for glycogen synthesis. Our failure to demonstrate 
an effect with in vitro administration of estradiol may be 
due to the relative insensitivity of skeletal muscle to the 
sex steroids. 
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Introduction 
The first attempts at understanding the interaction of 
sex steroids and carbohydrate metabolism showed that crude 
estrogenic preparations improved glycosuria in diabetic 
animals (6). Subsequent reports were contradictory, some 
showing exacerbation, and some, amelioration of experimental 
diabetes (42,128). Amidst the controversy, it was recognized 
that the effects on carbohydrate metabolism varied from 
animal to animal, steroid to steroid and at varying doses. 
More recent biochemical studies have examined the problem 
at a cellular level in a non-carbohydrate-intolerant animal 
model. 
The advent of oral contraceptives two decades ago intro¬ 
duced a nex-/ factor. Large numbers of women (currently esti¬ 
mated to be greater than 20 million world-xvide (194)) were 
taking agents whose metabolic side effects were not completely 
understood. The first reports suggesting such effects on 
carbohydrate tolerance appeared promptly; in 1963, Waine 
et al. (103) briefly reported on several patients who showed 
deterioration in their glucose tolerance on horethynodrel plus 
mestranol (Enovid). Since then, numerous studies have 
attempted to confirm or deny this observation. 
The present investigation was carried out to study a 
narrow portion of the overall problem: namely, does estrogen, 
specifically the naturally-occurring 17/3-estradiol, affect the 
insulin-mediated transport of glucose into muscle cells? The 

results of this work will be presented in the context of the 
existing data in animals and human subjects. Since the vast 
bulk of insulin-sensitive glucose utilization in physiologic 
states is by muscle and fat, the former was chosen as a model 
for insulin action 

Materials and Methods 
The method used was the rat diaphragm assay first 
described by Gemmill (63) and modified by others (19,23,27-28, 
technique consists of using the excised muscular portion of 
the rat diaphragm in vitro, (The method had been used exten¬ 
sively in measuring insulin-like activity before the advent of 
radioimmunoassay,) The muscle, when incubated in glucose- 
containing buffer solution with and without added insulin, 
takes up glucose from the medium. Glucose disappearance from 
14 
the medium, glycogen formation in the diaphragm or C -glucose 
incorporation into muscle have been used as markers of insulin 
action on carbohydrate metabolism. 
Animals 
Non-pregnant, adult, female rats of the Wistar strain 
(Camm Research, Wayne, N.J.) were used in all the experiments 
except for a small group of males studied for comparative 
purposes. All animals were kept in separate cages at least 
10 days prior to the experiment. They were allowed water and 
food ad libitum^ the diet consisting of Purina Laboratory Chow 
with the following composition: 
Protein 
Fat 
Fiber 
TDN 
NFE (difference) 
Kcal/Gm 
23.2% 
4.5 
3.8 
77.0 
52.5 
4.16 
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The animals were kept in a constant room temperature of 75-8Q°F 
with lighting from 6:00 a.m. until 6:00 p.m. 
Most animals did quite well under these conditions. When 
obtained from the supplier, these rats weighed approximately 
100 Gm. Weight gain ranged from 15-25 Gm. per week. Of the 
nearly 200 animals so treated, only three died before being 
sacrificed (none had been injected). Rats weighed 120-I80g 
at the time of study. 
Buffer Solution: 
Incubations were carried out in Krebs-Ringer bicarbonate 
buffer (105). As described by Umbreit et al. (195), solutions 
of the various components of the buffer were made up to con¬ 
centrations five times normal to improve stability. Buffer 
was prepared weekly from these stock solutions; the final in 
vitro concentrations are given below: 
(Reagent-grade chemicals in distilled I^O) 
NaCl 
KC1 
CaCl 
KH2PO4 
MgS04.7H20 
NaHC03 
0.154 M 
0.154 M 
0.110 M 
0.154 M 
0.154 M 
0.154 M 
The solution was gassed for 10 minutes with 95% 02/5% C02 to 
yield a final pH of 7.4. (3 -D-glycose was weighed and added 
to the buffer for a final concentration of 150 mg/100 ml. 
Solutions were stored in glass-stoppered bottles in a refrig¬ 
erator 
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Early work using the rat diaphragm was carried out in 
buffer media with added insulin. However, it has been shown 
in this system (34) as well as others that up to 80% of 
insulin can be lost by adhesion to glassware. Hence, 1% 
Bovine Serum Albumin (Sigma Chemical Co., Lot #33C-8160) was 
used to prevent this loss of insulin activity. 
Chemicals 
The insulin used was regular crystalline zinc insulin 
(Eli Lilly) obtained from the hospital pharmacy. Initially, 
U80 insulin (Lot #2L13854) was used with poor results. 
Improved biological activity (i.e., increased glucose uptake) 
was found using U100 regular insulin (Lot #6PW79C) and it is 
the latter which was used in all the experiments reported 
here. 
Insulin was prepared weekly by dilution of the vial 
contents in veronal buffer (barbital/Na diethylbarbiturate, 
0.02 M, pH=8.6) containing 2% Bovine Serum xAlbumin. The 
final insulin concentration was 0.1 U/ml; thus, 10 microliter 
aliquots added to 10 ml of Krebs-Ringer buffer yielded a final 
insulin concentration in the medium of 100 microunits/ml. 
17/3-estradiol (estra-'*'' ^^ -triene-3,17 -diol) was A 
grade, chromatographically pure steroid (California Biochemical 
Corp., Lot #201120) provided as the solid and refrigerated. 
For in vitro use: Peak plasma concentrations of estradiol 
in adult femal Wistar rats were shown by Brown-Grant et al. to 
* 
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be 30 pg/ml (22). Estradiol was weighed on a Sartorius 
Automatic Pre-weighing Balance (d<0.1mg) and dissolved in 
ethanol to a concentration of 1.0 mg/ml. Serial dilution 
in distilled water yielded final solutions of 0.5, 0.1, and 
0.05 ug/ml. One micro-liter aliquots of these solutions in 
1.0 ml incubation medium gave final concentrations approxi¬ 
mating 500, 100, and 50 pg/ml. Solutions of estradiol were 
prepared weekly and stored under refrigeration. 
For in vivo use; In attempting to arrive at a dose of 
estradiol which would approach the pharmacologic level of 
estrogen in oral contraceptives, it became evident that no 
firmly established amounts were recommended in rats. On the 
basis of the evidence quoted below* 10 ug/100 Gm body weight 
17/^-estradiol injected subcutaneously in sesame oil was chosen. 
*The most commonly-used estrogen derivatives in the oral con¬ 
traceptives are ethinyl estradiol and its 3-methyl ether, 
mestranol. Saunders (154) and Kind et al. (99) state that 
ethinyl estradiol and 17/3-estradiol have comparable estrogenic 
activity whereas Desaulles et al. (39), using vaginal epithelial 
cornification and inhibition of ovulation in the rat, believe 
that ethinyl estradiol possesses only l/10th the "estrogenic" 
activity of 17^-estradiol. Kind reports that mestranol possesses 
only l/5th the activity of the more potent estrogens. Using these 
rough criteria, one arrives at doses ranging from 0.02 to 0.2 
ug/100 Gm body weight of estradiol in women weighing 60-65 Kg. 
Studies in the rat yield somewhat different results. Basabe et 
al. (8) used 4 ug per day of estradiol in their rats weighing 
100 Gm. and above. Kind showed that a dose of 0.03 ug of 17/#- 
estradiol produced a significant pituitary effect and that 0.2 
ug total dose is needed for maximum inhibition of gonadotrophin 
secretion but does not report weights of the rats. Desaulles 
found that 3.0 to 10.0ug/100 Gm/day of 17^-estradiol injected 
subcutaneously in intact rats is sufficient to prevent ovulation. 
This is comparable to the smallest dose of estrone (1.0 ug/100 Gm) 
found by Saunders (151) to prevent conception, estradiol being 10 
times more potent than estrone as a uterotropic agent but only 2 
to 4 times as potent as a gonadotrophin inhibitor in spayed rats. 
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Solid estradiol was weighed and dissolved in a small amount 
of ethanol. The ethanol was removed by evaporation and 
reagent grade sesame oil was added to a concentration of 15 
3 
ug/0.1 ml estrogen. H-estradiol of known activity was dis¬ 
solved in a similar concentration and activity measured one 
week and one month later with no detectable separation of the 
estrogen. The solution was stable at room temperature. 
Animals were not anesthetized for injection; #25 needles were 
used to inject daily volumes up to 0.12 ml subcutaneously in 
the loose lower abdominal skin. 
Assays 
Insulin was measured by radioimmunoassay in Dr. Felig's 
laboratory. The technique is described elsewhere (149). 
Glucose determinations were carried out by the glucose 
oxidase method (85) using the Glucostat^ reagent kit 
(Worthington Biochemical Corporation, Freehold, N.J.). The 
method depends on the following sequence of reactions: 
Glucose + 02 -> H2^2 + Glucon:*-c Acid 
H2°2 + Reduced Chromogen -> Oxidized Chromogen + H20 
Vials of the enzyme, glucose oxidase, and the chromogen, o- 
dianisidine, are diluted with distilled water, a 1:20 Somogyi 
blood filtrate added, and incubation carried out at room 
temperature for ten minutes. This procedure had to be modi¬ 
fied for these experiments (150,205). 

a 
Deproteinization: 0.3 ml of the sample is pipetted 
into 4.5 ml distilled water using a Becton-Dickinson Biopette 
Automatic Pipetter. 0.9 ml of 0.34 N NaOH is added followed 
by, 1.0 ml of CDSC>4 solution (0.25% W/v), yielding a gelatinous 
precipitate. Following centrifugation at 3000 RPM for 15 
minutes at 3°C., 0.4 ml aliquots of supernatant could be used 
for glucose determination without interference from added 
albumin. 
Glucose determination: Instead of making up Glucostat 
reagent to the 60 ml total volume recommended by the manufac¬ 
turer, a more dilute solution (100 ml) was made up since it 
proved more useful. 6.0 ml of the dilute reagent was added 
to the deproteinized sample and incubated for 30 minutes at 
37°C. At the end of the precisely-timed incubation period, 
samples were removed from the bath, the reaction stopped 
with the addition of 2 drops 4.0 N HC1, and the tube allowed 
to stand at room temperature for ten minutes. 
Tubes were read in a Coleman Junior II Spectrophoto¬ 
meter at 425 nm, calibrated against blank and 50, 100 and 
150 mg% glucose standards. The standard curve was linear 
throughout the range studied and error was less than - 5 mg%. 
Description of the Rat Diaphragm Technique: 
All animals were fasted for 24 hours prior to the morning 
of the experiment but allowed water ad libitum. To minimize 
diurnal variations, animals were sacrificed between 9:00 a.m. 
and 11:00 a.m. Three to four animals were used each day. In 
those animals receiving injections of estrogen, no dose of 
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estradiol was given on the morning of the sacrifice of the 
rat. 
Animals were decapitated using a guillotine (Harvard 
Apparatus) and allowed to exsanguinate. Within one minute, 
the abdomen was quickly opened in a V-shaped incision carried 
from the suprapubic area to the lateral rib cage bilaterally. 
This procedure effectively exposes the xiphoid process which 
r 
was then grasped with a hemostat and lifted superiorly and 
caudally, exposing the abdominal aspect of the diaphragm. At 
this point, peristalsis and cardiac fibrillation was still 
present. A nick was made in the central portion of the dia¬ 
phragm, the resulting loss of the negative intrapleural 
pressure causing the diaphragm to billow out into the abdomen. 
Using 1/4 inch straight scissors, the diaphragm was incised 
at its xiphoid insertion. The incision was then carried 
around both borders interiorly, staying as close ho the 
thoracic wall as possible and attempting not to cut a ragged 
or scalloped edge. When freed from its circumferential 
attachment, the thoracic aspect of the diaphragm was care¬ 
fully exposed, adherent pleura removed, and a hemostat 
placed on the inferior vena cava on both sides of the dia¬ 
phragm. The IVC was then transected in its thoracic portion 
first, between hemostat and diaphragm. The aorta could be 
divided with no bleeding and the adherent lungs bluntly 
dissected away. Returning to the abdominal surface of the 
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diaphragm, the inferior vena cava and the tightly-adherent 
hepatic ligaments were divided. In practice, this latter 
portion of the dissection is invariably bloody and any 
attempt to prevent injury to the liver would have so pro¬ 
longed the removal of the diaphragm that the best course was 
to keep the muscle as far as possible from the pool of blood 
that gathers promptly upon separation from the liver and to 
quickly sever the remaining connections to the posterior 
thoracic wall. 
The excised, \tfhole diaphragm was placed in 5 ml iced 
Krebs-Ringer buffer in a glass petri dish (saturated with 
°2//C02 but contain*n9 no glucose or insulin). The central 
tendinous and membranous portion was separated from the more 
peripherally-located muscle, the cut edge trimmed, fat 
removed, and blood in larger vessels gently expressed out. 
The final specimen had a horseshoe shape as in Figure IB. 
Depending on the experiment, one or three cuts were made to 
yeild hemi- and quarter-diaphragms, respectively. 
Fig. 1 Appearance of excised rat diaphragm immediately after 
removal from animal (A) and prior to incubation (B). 
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Incubation: 
Slices of muscle were transferred to a clean beaker 
containing 10 ml of buffer with glucose (150 mg%) but no 
albumin or insulin, and the solution gently bubbled with a 
gas mixture of 95% 02/5% CO, for 15 minutes at room tempera¬ 
ture. This preincubation period served several purposes: 
1. Saturation of tissues with oxygen. 
2. Washing blood, tissue fluid and endogenous 
insulin from muscle. 
3. Allowing smoother equilibration of tissue 
from its Ooc. wash medium to the 37° incubation 
medium. 
4. Removal of endogenous insulin activity as a 
factor by approaching half-life in vitro. 
5. The presence of a high physiological concentration 
of glucose in the pre-incubation stage would pre¬ 
sumably provide a more reliable baseline for the 
subsequent incubation since mass action movement 
of glucose into cells would be minimized. 
At the end of the preincubation period, the tissue was 
removed from the buffer, gently blotted on filter paper, and 
placed in a 10 cc Erlenmeyer flask containing 1.0 ml of buffer 
with glucose (150 mg%), albumin (1%), and without or with 
insulin (100 uU/ml). After making certain that all the tissue 
in the flask was immersed in the medium, the neck was sealed 
with a rubber bung. Two #19 needles were inserted through 
the bung and used to fill the flask with 95% Q?/5% CO^ (Figure 
2). 
fia s 
Figure 2 

12 
The flasks were incubated at 37°C. in a Dubnoff 
Metabolic shaking incubator at 100 oscillations per minute. 
After three minutes, the needles were removed from the rubber 
bungs and the flasks remained sealed for the duration of 
incubation, 57 minutes. At the end of this period, the 
flasks were removed from the bath, placed in ice to stop 
further reaction in the muscle, and the tissue carefully 
removed with a fine-toothed forceps. Each piece of muscle 
was weighed on a Mettler P163 Balance (d=l mg) after being 
blotted on filter paper. Tissue weight is thus the wet 
weight. 
Calculations: 
Glucose concentration at the start of incubation was 
measured from the stock solution prepared for each day’s 
experiments. Final glucose concentration in each flask was 
determined in duplicate samples as described above. Knowing 
the change in glucose concentration per 100 ml (e.g., A = 
50 mg%), the uptake of glucose per 1.0 ml of medium by the 
muscle strip is easily obtained (0.5 mg). This value is 
divided by the wet weight of the tissue in the flask in 
grams and the glucose uptake finally expressed as milligrams 
glucose taken up per gram wet weight of muscle per hour 
(mg/g/hr). 
Experiments: 
1. In vitro: For these experiments, the diaphragm of 
each animal was divided into quarters, yielding one control 
and three portions undergoing treatment. The following groups 
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of experiments were performed: 
1. Control (with and without insulin) 
2. Estradiol in vitro with and without insulin 
3. Pre-incubation with estradiol followed by 
incubation with estradiol 
4. Incubation with ethanol (control for estradiol 
diluent) 
When "pre-incubated", the tissue was exposed to various con¬ 
centrations of estradiol in the preincubation stage before 
transfer to the incubation medium where the same concentration 
of estradiol was present. In all these studies, each animal 
served as its own control. 
2. In vivo: In these experiments animals pretreated 
with estrogen for 2 weeks were compared to vehicle-treated 
controls. The diaphragms were divided into 2 equal halves 
and incubated as described above but with only insulin added. 
Obviously, total glucose uptake in this latter technique was 
higher than with smaller amounts of tissue per flask (i.e., 
quarter-diaphragms) with less variability in the assay. 
Group I, controls. 
Group II, estrogen pretreated. 
A subgroup of Groups I and II animals was used to deter¬ 
mine fasting blood sugars and immunoreactive insulin (IRI) 
levels. Since it was not practical to collect blood samples 
after decapitation (tissue factors increasing coagulability, 
relatively small volumes obtainable, need for quick removal 
of the diaphragms), vena caval puncture was performed under 
ether anesthesia. Samples were collected in heparinized 
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tubes, centrifuged at 5,000 RPM at 3°C. for ten minutes, 
and plasma stored at -5°C. for insulin and glucose determin¬ 
ations . 
Statistical Analysis: 
Due to the number of groups being compared with resultant 
large numbers of comparisons, a simple t-test for significance 
was not appropriate. Hence, all experiments were initially 
analyzed according to a repeated measures analysis of variance 
design. Specifically, the analyses were considered to be as 
follows (* indicates the repeated measure factor): 
In vivo experiments (pretreatment with estradiol): 
Subjects (rats) nested in pretreatment (with or 
without estrogen) crossed with treatments (with 
or without insulin in vitro).* 
In vitro experiments: 
1. Control 
2. Estradiol Subjects X treatment 
3. Ethanol where each subject 
4. Preincubation with acted as its control, 
estradiol 
Where an omnibus F-test in the analysis of variance proved to 
be significant, differences between the means of individual 
groups were tested for significance using the Newman-Keuls 
procedure for evaluating q, the studentized range statistic 
q = X2 - X! 
o—# 
(S.e.)- 
where 
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The Neuman-Keuls procedure corrects significance estimates 
for the effect of multiple comparisons in relation to the 
actual degrees of freedom. These adjusted probabilities are 
a fairer and more conservative estimate of the significance 
of difference between means than a simple t-test. 
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Results 
1, In vitro treatment of quarter-diaphragms. 
A. Variation of total weight of diaphragm 
Since it seemed likely that some of the rat-to-rat 
variation in insulin responsiveness of the tissue was due 
to different weights of animals (cf. Liebecq, 113), rat 
weight at the time of sacrifice was examined in relation to 
the total wet weight of the diaphragm after incubation. 
There was a significant relationship that was linear in 
nature in the weight range of the rats used in these exper¬ 
iments (Figure 3). 
\JeR<*V ) 
Figure 3 Increase in wet weight of total diaphragm with 
increasing weight of rat 
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B. Control Experiments 
A large number of preliminary experiments was conducted 
initially in order to test the reliability of the results with 
the rat diaphragm assay. A final group of ten animals is 
presented as an internal control for the techniques used, 
although these results do not enter into the statistical 
analysis of subsequent experiments. Animals were sacrificed 
on three days with conditions as constant as possible. Of 
the four quarter-diaphragms from each animal, 2 were incubated 
in glucose without insulin and 2 in glucose plus insulin 
(100 uU/ml). The results are described in Fig. 4, 
Figure 4. Control. Mean glucose uptake ±S.E.M. In basal 
and Insulin-treated quarter&laphragms. 

18. 
The analysis of variance (Appendix A) showed that 
treatment with insulin had a highly significant effect 
(p <.001) by omnibus F-test. The four groups were then 
compared by calculating q (See Table 1). Insulin-treated 
groups (III and IV) were significantly different (p<.01) 
from control groups (I and II). The differences between 
similarly-treated groups were not significant. 
TABLE 1 
. f 
Mean Glucose Uptake (- S.E.M.) by Quarter-diaphragms (Control) 
Control (n=10) Insulin (n=10) 
I II III IV 
2.65±0.33 2.63-0.33 4.33-0.36 4.33-0.38 
TABLE 2 
Significance of differences between means for Control Experiment 
Groups Tested q-test Significance (p) 
I vs. Ill 19.99 < .01 
I vs. IV 20.00 < .01 
II vs. III 20.03 < .01 
II vs. IV 20.05 < .01 
I vs. II 0.29 NS 
III vs. IV 0.04 NS 
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C. In vitro 17^-estradiol 
In these experiments, the effect of 17/^-estradiol (500 
-3 pg/ml, 2 x 10 uM) was tested in vitro using each animal as 
its own control. A total of 23 rats was used; in 15, quarter- 
diaphragms were treated as I, control; II, insulin (100 uU/ml); 
III, insulin + estradiol; IV, insulin + estradiol. In the 8 
remaining animals the fourth quarter-diaphragm was used in 
other experiments. The overall results are shown in Figure 
5. 
Figure 5 Mean glucose uptake -S.E.M. for basal, insulin- 
treated and insulin + estrogen-treated rat quarter- 
diaphragms in vitro. 
t , 
f iX 
•* 
t , 
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The statistical analysis was carried out in 2 groups: 
the first where n«23 in which the "treatments" are I# 
Control; II, insulin; and III, insulin -f estrogen (Tables 3 
and 4, Appendix 3) shows that treatment overall had a highly 
significant (p<.001) effect but that concurrent treatment 
with estradiol in vitro did not alter glucose uptake when 
compared to insulin alone. 
TABLE 3 
Mean Glucose Uptake (isEM) by quarter-diaphragms. Control^ 
insulin-treated and insulin + estradiol 
n=23 
Control (I) Insulin (II) Insulin + Estradiol (III) 
3.74^0.22 5.25^0.27 5.28-0.26 
TABLE 4 
Significance of the differences between 
estradiol 
n=23 
means for in vitro 
Groups Tested q-test Significance (p) 
I vs. II 15.82 < .05 
I vs. Ill 15.63 < .05 
II vs. Ill 0.27 NS 
If the data is analyzed in the 15 animals in which two 
quarter-diaphragms were treated with insulin and estradiol 
(Appendix C, Tables 5 and 6), the results are essentially the 
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same: in vitro estradiol had no effect on insulin-mediated 
glucose uptake at incubation periods of 1 hour. 
TABLE 5 
Mean Glucose Uptake (-S.E.M.) by Quarter-diaphragms. Control, 
insulin-treated, and insulin + estradiol (in 2). 
n=15 
Control (I) Insulin (II) Insulin+Estradiol (III,IV) 
3.67±0.31 5.21-0.25 5.25-0. 34 5.08-0.37 
TABLE 6 
Significance of the : differences between 
estradiol 
n=15 
means for in vitro 
Groups Tested q-test Significance (p) 
I vs. II 13.04 < .01 
I vs. Ill 13.35 < .01 
I vs. IV 11.92 < .05 
II vs. Ill 0.31 NS 
II vs. IV 1.11 NS 
III vs. IV 1.42 NS 
In a small group of animals (n=4), basal glucose uptake 
(no insulin added to incubation buffer) was compared between 
quarter-diaphragms from the same animal with and without the 
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_3 presence of estradiol 2 x 10 uM. The difference between the 
two groups was not significant by t-test (Table 7). 
TABLE 7 
Mean Glucose Uptake (^S.E.M.) by Quarter-diaphragms in vitro 
with and without estradiol 
(Basal) 
Control -j-Estradiol 
3.59-0.38 3.53-0.29 
The effect of the small quantities of ethanol used to 
dissolve the 17/3-estradiol were examined (See Appendix D, 
Tables i and ii), and found to have no significant effects 
on either basal or insulin-mediated glucose uptake. Figure 
6 shows the results when ethanol was added to insulin. 
Figure 6 Mean glucose uptake is.E.M. in basal, insulin-treated 
and insulin + ethanol-treated quarter-diaphragms 
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D. Pre-incubation with 17^-estradiol 
In this set of experiments, estradiol was added to the 
pre-incubation buffer in a concentration of 2 uM. There was 
no added insulin until the diaphragm was transferred after 15 
minutes to the usual incubation medium. The pre-treated 
quarter-diaphragm was incubated in the presence of the usual 
_3 
(2 x 10 uM) amount of estradiol. The results are described 
in Figure 7 and Tables 8 and 9. There was no significant 
effect of pre-incubation with estradiol, representing a total 
of 75 minutes in which the tissue was in contact with estro¬ 
gen in vitro. (Analysis of Variance, Appendix E.) 
Figure 7 Mean glucose uptake -S.E.M. in basal, insulin- 
treated, and estradiol-preincubated followed by 
insulin-treatment rat quarter-diaphragms. 
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TABLE 8 
Mean Glucose Uptake (-S.E.M.) by Quarter-Diaphragms. Pre¬ 
incubation with 17^-estradiol 
n=9 
Control (I) Insulin (II) Insulin, estradiol (in: 
3.22^0.26 4.66-0.19 4.60-0.28 
TABLE 9 
Significance of the 
insulin 
differences between 
(II) and estradiol 
means for Control 
preinc (III) 
(i) 
Groups Tested q Significance (p) 
I vs. II 11.74 
i
 
i
 
in
 
o
 
•
 
V
 
I vs. Ill 11.25 < .05 
II vs. Ill 0.82 NS 
2. In vivo pretreatment of rats with 17/^-estradiol followed 
by incubation of hemidiaphragms with and without insulin 
A. Variation of total weight of the diaphragm 
Figure 8 shows the results of two weeks' pretreatment of 
two groups of rats. Group I with sesame oil. Group II with 
17/3-estradiol (10 ug/100 Gm body weight) injected subcutaneous¬ 
ly. Group I (n=19) rats weighed 151.9-3.03 Gm (Mean-S.E.M.) 
and Group II, 152^3.56 Gm at the time the animals were sacri¬ 
ficed. This represents no significant difference. 
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Comparison of Figures 8 and 3 reveals that the slopes 
of the lines describing the increase in diaphragm weight as 
a function of animal weight are similar for animals that did 
and did not receive pretreatments by subcutaneous injection. 
In general, however, the total diaphragm weights are greater 
in the pretreated group because these muscles were prepared 
as hemidiaphragms and hence required less trimming. 
Figure 8. Total weight of diaphragm vs. weight of rats 
injected with sesame oil with and without estradiol for 
two weeks. 
B. Fasting plasma glucose and IRI concentrations 
Since the hemidiaphragms used in these experiments came 
from animals which had received sesame oil with and without 
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estrogen, an analysis had to be carried out comparing the 
two groups, two "pretreatments" (with and without estrogen), 
and two "treatments" in vitro (with and without insulin). 
In order to determine more precisely the effects of 
estrogen pretreatraent, two subgroups were used to determine 
fasting glucose and insulin levels. Table 10 shows that 
there were no differences in final weights of the animals, 
plasma glucose or immunoreactive insulin concentrations 
after 2 weeks pretreatment and 24-hour fast. 
TABLE 10 
Mean (-S.E.M.) Fasting Plasma Glucose (mg%), IRI (uU/ml) and 
Weight (Gm) in Rats with and without Estrogen Pretreatment 
(n=10) 
Weight (Gm) Glucose (mg%) IRI(uU/ml) 
Pretreatment with 
sesame oil alone 155-8.3 99.2-3.7 34.0^2.8 
Pretreatment with 
estradiol 158^5.2 97.6i3.9 33.3±2.9 
Significance (p)* NS NS NS 
*By student*s t-test. 
C. Analysis of Data on Glucose Uptake 
In Figure 9 glucose uptake per hemidiaphragm is plotted 
as a function of the weight of the animal. There is a con¬ 
sistent tendency for the muscle of smaller animals to take up 
more glucose per gram wet weight than that of larger animals 
. 
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in both basal and insulin-stimulated states. This confirms 
observations made by Liebecq (113). While his data show a 
non-linear relation at the lower weight range, none of the 
animals used in the present study were lighter than 120 
grams; the regression lines are significant only for the 
estrogen pretreated animals and are shown only to indicate 
the general trend. 
Figure 9« Relationship of glucose uptake to weight of 
rat in estrogen-treated (basal0 , 4-insulin* ) and non- 
estrogen-treated (basalO, 4-insulin#) rats. 
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Table 11 shows the compiled data for glucose uptake in 
the basal and insulin-mediated states following in vivo pre¬ 
treatment of Group I rats with vehicle alone and Group II 
with estradiol. 
TABLE 11 
Mean Glucose Uptake (-S.E.M.) in Hemidiaphragms, Effect of 
Pretreatment with Estradiol 
Pretreatment in vivo 
N Vehicle alone Estradiol 
Basal (no insulin) 19 3.49-0.06 2.91-0006 
Insulin (100 uU/ml) 19 4.82-0.06 5.88-0.06 
The analysis of variance (Appendix F) indicated that pre¬ 
treatment significantly (p®Q.0Q5) affected glucose uptake by 
an omnibus F-test. Similarly, insulin treatment and the 
interaction of pre-treatment and treatment showed highly sig¬ 
nificant effects (p< 0.001). 
Figure 10 and Table 12 show the effect of estradiol pre¬ 
treatment on the insulin uptake of heraidiaphragms in the 
basal state and in the presence of insulin. There are sig¬ 
nificant differences in both conditions (p^.QOl), estradiol 
causing a 16% decrease in basal uptake and a 22% increase in 
insulin-stimulated uptake 
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<£J.O01 p> 
Figure 10. Mean glucose uptake (±S.E.M.) in basal and 
insulin-stimulated rat hemidiaphragms showing the effects 
of estrogen pretreatment. 
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TABLE 12 
Significance of the differences between means for glucose uptake 
of hemidiaphragms from pre- and non-pre¬ 
treated rats (estradiol for 
BASAL 
2 weeks) 
Mean SD N Variance 
Group I (no estrogen) 3.49 0.27 19 0.074 
Group II (+ estrogen) 2.91 0.24 19 0.059 
Difference SE df t-test P 
0.575 0.086 36 6.708 <.001 
INSULIN-STIMULATED 
Mean SD N Variance 
Group I 4.82 0.26 19 0.066 
Group II 5.88 0.26 19 0.069 
Difference SE df t-test P 
1.065 0.087 36 12.309 <.001 
In Figure 11, the relative effects are plotted with 
estrogen pretreatment as the independent : variable . Of note 
is that the effects of estrogen in vivo on muscle uptake of 
glucose in vitro are not parallel in basal and insulin-stimulated 
states; specifically, there is a 16% decrease in basal and a 
22% increase in insulin-stimulated glucose uptakes with estro¬ 
gen pre-treatment as compared to control. The relatively 
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larger increment in the latter condition cannot be accounted 
for by the change in basal uptake, which is in the opposite 
direction. In fact, when examined in this fashion we can 
designate the change in glucose uptake (as % of basal uptake) 
as "insulin effect". Thus, the insulin stimulatory effect in 
untreated animals is 38% whereas in estrogen-treated animals 
it is 103%. This represents a greater than two-fold increase 
in insulin sensitivity. 
■5 
f 
% 
J 
Animals x 2. Animals pnrtveafadl X2 u«cKs 
Wee.Us toitfa sesame, oil uxt^i <7(1-tMmauiioI in sesame <■>« I - 
Figure 11. Relative effects of estradiol pretreatment on 
mean glucose uptake (±S.D.) for basal and insulin-stimul¬ 
ated hemidiaphragms. The effeot of estradiol was signi¬ 
ficant on both basal and insulin-mediated gluoose uptake. 
See text. 
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Summary of the Results 
1) Using the rat diaphragm in vitro assay for the action 
of insulin on glucose, uptake by muscle is sensitive at 
physiologic levels of insulin and the differences in 
glucose uptake between insulin-treated and untreated 
muscle are significant. 
2) There is no significant effect of high pharmacologic 
concentrations of 17/^-estradiol on either basal or 
insulin-stimulated glucose uptake for incubation periods 
up to 75 minutes when added in vitro. 
3) Pretreatment of rats with estradiol for 2 weeks resulted 
in no significant changes in weight gain as compared to 
controls. 
4) Estradiol pretreatment did not alter fasting plasma 
glucose or insulin concentrations. 
5) Estradiol pretreatment caused a significant decrease (16%) 
in glucose uptake in the basal state as compared to 
controls. 
6) Estradiol pretreatraent caused a significant increase (22%) 
in glucose uptake in the insulin-stimulated state as 
compared to controls. 
The effect of estrogen pretreatment on insulin-stimulated 
glucose uptake could not be explained by its effects on 
basal uptake. There is thus a greater than two-fold 
increase in insulin responsiveness of the muscle from 
estrogen-treated animals. 
7) 

Discussion 
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I. Animal Studies 
Following the discovery that anterior pituitary extract 
was diabetogenic in the rat and that hypophysectomy ameliorated 
the diabetes (83), interest arose in the relationship of sex 
hormones to diabetes. Thus, the experimental-diabetic animal 
was the earliest model for the study of the influence of 
estrogen on carbohydrate metabolism. 
Barnes et al. (6) found that the administration of crude 
estrogenic preparation (amniotin) decreased glycosuria in 
pancreatectomized dogs. Similarly, Nelson and Overholser (218), 
in a small group of totally pancreatectomized Rhesus monkeys, 
found estrone treatment improved survival of the animals and 
that increasing the dose of estrone decreased the glycosuria. 
Contradictory evidence was presented by Dolin et al. (42) 
who failed to demonstrate improvement in experimental diabetes 
in ferrets; in fact, in 90%-pancreatectomized female ferrets 
receiving estradiol benzoate, glycosuria and acetonuria 
increased. Young (216), using doses of estrogen higher than 
those reported by Barnes and Nelson, was surprised to find 
that diethylstilbestrol (DES) had no effect on diabetes while 
estriol and estrone exacerbated diabetes mellitus in dogs 
made diabetic by injection of anterior pituitary extract. At 
the same time, Ingle (86) demonstrated that DES administered 
to partially pancreatectomized non- or mildly glycosuric 
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rats resulted in severe glycosuria and hyperglycemia. He 
obtained similar though somewhat less striking results with 
estradiol. In normal rats on a high carbohydrate diet, DBS 
induced a mild, temporary glycosuria. Using the same system, 
he went on to show (87,88) that treatment with DBS in intact 
animals required larger doses of estrogen to produce this 
transient glycosuria (weeks) than in diabetic animals in 
which the effect persisted for the length of the experiments 
(months). Similar results were obtained by James et al. (90). 
These studies were certainly suggestive of some effects of 
estrogen on carbohydrate metabolism in diabetic and normal 
animals, but the differing animal models, estrogen prepara¬ 
tions and doses, extent of pancreatic ablation, duration of 
treatment and criteria for study make evaluation of the evi¬ 
dence difficult. 
The South American group of Iloussay, Foglia, Rodriguez 
and their coworkers performed similar experiments with the 
advantages of uniformity of techniques and adequacy of con¬ 
trols . 
Two sets of experiments were performed by Foglia et al. 
(54,59) on the incidence of diabetes following subtotal (95%) 
pancreatectomy in male and female rats. Males did quite 
poorly with 100% developing diabetes in six months (fasting 
blood sugars 150 mg% and fasting glycosuria), while only 20% 
of females became diabetic. When the animals were paired-fed 
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(i.e., male fed only as much as female), the percentage 
diabetic at 2 months was 100 for males and 60 for females. 
In forced-feeding experiments conducted for 40 days, 60% of 
males and 15% of females became diabetic. 
The effect of the gonads was studied by castration 
followed by pancreatectomy. When castration was performed 
at birth, 80% of animals, both male and female, became dia¬ 
betic 6 months after subtotal pancreatectomy. If, however, 
pancreatectomy preceded castration, 100% of intact males, 80% 
of castrated males, 40% of castrated females, and 20% of in¬ 
tact females developed diabetes in six months. When allowed 
to go to one year, only 50% of gonadally intact females became 
diabetic. This evidence was interpreted as showing a "pro¬ 
tective " effect of the ovaries on the development of experi¬ 
mental diabetes in the rat. 
The problem was further studied by Foglia (59) who showed 
that exogenously-administered sex steroids affected the 
incidence of diabetes in 95%-pancreatectomized rats. The data 
are summarized in Table I below. The statistical significance 
TADLE I 
Incidence of diabetes in rats castrated at 80-100 Gm body weight 
and 95% pancreatectomized one week later, injected daily for six 
months with subcutaneous doses, on ad libitum normal carbohydrate 
content diet (from Houssay et al. (84)1. 
Percent Diabetic © 6 mo 
Dose (ug) Female {n=116) Male (n=43) 
Control 46 89 
Estrone 15 30 
Estrone 50 0 
Estradiol 15 12 66 
DES 15 30 
DES 50 12 50 
Ethinylestradiol 50 25 
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of these data is uncertain although the numbers of animals 
are sufficiently largo to suggest that these differences are 
meaningful. Similar data was obtained in intact and castrated 
female rats using estradiol benzoate (see Table II). This 
evidence points to a protective effect on the development of 
diabetes of naturally-occurring and synthetic estrogens in 
pharmacoligic doses. 
TABLE II 
Effect of estradiol benzoate injected daily for six months 
on the incidence of diabetes {%) in intact and castrated male 
and female rats after 95% pancreatectomy (from Lewis et al. (112)) 
Female Male 
Intact Castrate Intact Castrate 
Dose (ug) 
Cont Rx Cont Rx Cont Rx Cont Rx 
2 43 8 22 16 92 36 61 36 
4 21 0 37 8 88 50 87 44 
15 71 33 86 12 100 16 100 66 
The time course of the appearance of diabetes is impor- 
tant, Lewis et al. (112) found that after 95% pancreatectomy, 
diabetes develops in three stages: 
1. "pre-diabetes" -- one to two months of normal 
growth, normoglycemia and no glycosuria 
2. "incipient diabetes" — normoglycemia and no 
fasting glycosuria but post-prandial glycosuria 
. "manifest diabetes" — fasting hyperglycemia, 
glycosuria and death when not treated 
3 
- 
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This type of experimentally-induced carbohydrate in¬ 
tolerance Houssay (84) calls "pancreatic diabetes" in con¬ 
trast to alloxan diabetes. Both are worsened by increased 
food intake and are affected by thyroidectomy and corticos¬ 
teroids. However, the acutely-induced diabetes with alloxan, 
pituitary extract or total pancreatectomy is different in that 
the animals must be maintained on exogenous insulin from the 
immediate post-treatment period. In these animals estradiol 
benzoate causes a transient exacerbation of the diabetes but 
the animals do not benefit from long-term estrogen thereapy. 
As we have seen, this is in contrast to the subtotally-pan- 
createctomized animal which after transient exacerbation, 
improves with long-term estrogen (146). If the animal was 
already overtly diabetic, adrenalectomy did not have an 
effect on the course (84). 
This evidence was seen to point toward several possi¬ 
bilities: increased availability of insulin, increased 
sensitivity to endogenous insulin, inhibition of some "dia¬ 
betogenic" factor, or direct effects of estrogens on glucose 
utilization or production. Anatommic data compiled by this 
group was used to support the first hypothesis with the 
reasoning that when pancreatectomy is partial, chronic estro¬ 
gen administration leads to increased insulin secretion. The* 
insulin content of the pancreas is similar in male and female 
rats and is not changed by castration (75) but the volume of 
; •. rx 
, 
. 
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islet tissue was said to be greater in female rats (190). 
Estrogen treatment increases the insulin concentration of 
the rat pancreas with hyperplasia and sometimes hypertrophy 
of islet cells (146). This is in contrast to the lesser 
degree of hyperplasia seen in non-estrogen-treated rats and 
is said to be associated with degranulation of beta cells. 
The duration of time required for this effect at the dose 
used (15 ug/rat/day) is 2-3 months. Foglia (58) found that 
in castrated, hypophysectomized, 95%-pancreatectomized female 
rats, 4 ug estradiol benzoate per day was better than saline 
in ameliorating diabetes after 3 months. Again, the pan¬ 
creases of estrogen-treated animals showed an increase in the 
number and size of islets. Girod and Czyba (68) confirmed 
this histologic finding; they demonstrated that estrogen 
increased the percentage of beta cells in islets in the head 
of the pancreas. 
More recently, Basabe et al. (8) have measured blood 
glucose and plasma insulin concentrations in castrated female 
rats treated with several steroids. The only group showing a 
significant (but small) increase after treatment had been 
treated with 17/3-estradiol. These changes were not evident 
until quite late; however, blood glucose did not show any 
significant difference until 6 months after treatment was 
instituted, while 2 months were required for significant 
fasting insulinemia to appear. 
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The authors did not interpret the data as indicating a 
diabetogenic effect of estrogen treatment. However, it is 
of note that plasma insulin levels were elevated earlier than 
changes in glucose concentration became evident, and only 
when insulin levels were 1.5-2-fold above control did blood 
sugars fall significantly. At no time were there significant 
increases in blood sugar. An alternative hypothesis would 
be that blood sugar is not a sensitive enough indicator of 
the peripheral action of insulin and that the hyperinsulinemia 
was indeed in response to peripheral antagonism to insulin- 
mediated glucose utilization by tissues not sufficient to 
raise plasma glucose values. It is unlikely that the effects 
were secondary to obesity or age since matched controls 
injected with olive oil alone showed no significant elevations 
of plasma insulin. 
Costrini and Kalkhoff (30) incubated slices of rat 
pancreas in vitro and measured immunoreactive insulin release 
after glucose stimulus. Estradiol benzoate in vivo increased 
the insulin secretion of the tissue significantly. This 
effect was seen after three weeks' treatment. In addition, 
post-estrogen treatment glucose concentrations in intravenous 
glucose tolerance tests (IVGTT) were lowered significantly. 
This betacytotrophic effect of estrogen was thus postu¬ 
lated on largely indirect evidence. Rodriguez (146) attempted 
to demonstrate a direct effect by implanting pellets of 
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estradiol in the rat pancreas in vivo. He found that islet 
size increased focally the nearer the pellet. 
There is conflicting evidence on thi3 point. Hager et 
al. (74) treated rats with progesterone, estradiol, and human 
chorionic somatomammotropin and meas red insulin secretion 
from their pancreases in vitro. sterone increased insulin 
secretion but no further increment 
were treated with both estrogen ai ogesterone. Estradiol 
alone led to a smaller than norma ulin secretory response 
to glucose stimulation. 
Recently, Bailey and Matty (4} f md that in vitro 
incubation of pancreatic tissue for 6 hours with estradiol 
does not affect the insulin secretor 
does. 
The state of granulation of the beta cells may not 
reflect the insulin content of 
changes in the amount of acinai can result in changes 
in insulin concentration in the pancx >a -ithou, t' ei 
any change in the total amount of insulin in the gland (75). 
One must conclude, therefore, that the evidence is inconclu¬ 
sive as to whether estrogen promotes insulin secretion by a 
direct betacytotropic effect. 
The findings by Houssay and Foglia that estrogens have 
a protective effect on the development of diabetes and can 
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improve the degree of glycosuria in the diabetic animal is 
compatible with our results showing an enhancement of glucose 
uptake in the insulin-stimulated state in animals pretreated 
with estrogen. Contrary to the previous studies, we have 
found that estrogen (specifically 17/^-estradiol) increases 
the insulin sensitivity of skeletal muscle and thus do not 
need to postulate an increase in endogenous insulin produc¬ 
tion with estrogen treatment. It was only in 95%-pancreatec- 
tomized animals that Houssay and Foglia demonstrated a bene¬ 
ficial effect of estrogen. We propose that the enhanced 
response of skeletal muscle to the remaining small endogenous 
insulin output of these animals would account for the observed 
effects with estrogen treatment. 
We found that short-term treatment with estradiol was 
not associated with changes in fasting insulin or glucose 
concentrations. We did, however, find that the diaphragm 
muscle of treated animals took up less glucose in the basal 
state when compared to control. One might expect this rela¬ 
tive deficit (about 20%) in glucose uptake in vitro to be 
reflected in the fasting in vivo glucose concentration. 
There are two related explanations for this apparent contra¬ 
diction. In the post-absorptive state (i.e., after a 24-hour 
fast as in our animals) the vast bulk of circulating glucose 
is taken up by non-insulin-dependent tissues, mainly neural. 
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with muscle metabolism relying largely on fatty acids and 
ketone bodies as sources of energy. Even when glucose, 
insulin and fatty acids are present in greater concentrations 
(e.g., after a meal) glucose accounts for as little as one 
fifth of the oxidative metabolism in muscle. Thus, even a 
relatively large change in muscle uptake of glucose in the 
fasted state would not affect overall blood glucose levels 
significantly. 
The suggestion that insulin action may be enhanced by 
other hormones has received little attention. Talaat et al. 
have studied the effects of estradiol dipropionate in rabbits 
(187) and in women (189). In their animal studies, intravenous 
glucose tolerance tests (IVGTT) were performed on ovariectom- 
ized and intact female rabbits after 3 and 7 days of intra¬ 
muscular estrogen (0.02 mg/kg/day). They found that: 
1. after 7 days* treatment, there were sig¬ 
nificant decreases in 30 and 60 minute 
blood glucose and increased sensitivity 
to insulin lasting up to three days after 
treatment was discontinued 
2. ovariectomy caused a significant rise in 
the glucose tolerance curves 2 and 4 weeks 
post-operatively; ovariectomy caused a de¬ 
crease in sensitivity to exogenous insulin 
as measured by % reduction of fasting glu¬ 
cose. 
These data confirm our own observations that the enhanced 
response in muscle is seen with insulin treatment. These 
effects in the intact animal were small and no changes were 
observed in fasting blood sugars. 
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Similar investigations were carried out in normal 
volunteers and insulin-dependent diabetics (women) (189). 
Doses of estradiol diproprionate (5 mg every other day for 
7 to 12 days) caused a significant lowering of the fasting 
serum glucose concentrations in both arterial and venous 
samples of the normal women. The effect of a single dose 
of 25 mg of estradiol resulted in a significant increase in 
glucose utilization at 60 and 90 minutes of the oral glucose 
tolerance test. These effects were not seen in diabetics. 
Talaat and his coworkers interpreted these results as 
showing that estrogen stimulation of beta cells improves 
glucose tolerance in normal women whereas in diabetics an 
absent endogenous insulin production precluded such effects. 
They did not perform insulin assays on their subjects and 
our studies would suggest a different mechanism to account 
for the observed increase in glucose utilization. It is 
difficult to understand two of their findings: first, the 
decrease in fasting blood sugar with estrogen treatment, 
and, second, the lack of any observed action in diabetics 
who were receiving exogenous insulin. 
It would appear, then, that carbohydrate tolerance is 
affected when estrogenic substances are administered. There 
are earlier data to support our findings that glucose tolerance 
may be improved. However, the proposed mechanism, namely that 
of stimulation of endogenous insulin secretion by estrogen. 
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is neither satisfactory nor clearly established. The present 
study has shown that increased sensitivity to insulin of 
skeletal muscle may play a role in the enhanced uptake of 
glucose by this tissue. A brief survey of the action of 
these hormones at a cellular level may be appropriate. No 
attempt at a complete review will be made here since the 
reader can refer to excellent recent papers by Jensen et al. 
(92) on sex steroids and by Levine (111) and Cuatrecasas (33) 
on insulin. 
The action of insulin on glucose metabolism is not com¬ 
pletely understood but it is clear that at least two functions 
can be ascribed to insulin in muscle: 
1. promoting glucose transport into cells, and 
2. increasing glucose utilization, probably by 
increasing the activity of glycogen synthe¬ 
tase. 
In the experiments reported above, we could not differentiate 
between these two functions since glycogen formation was not 
measured. It is, therefore, possible that estrogen affected 
either or both the above pathways of insulin action. 
It is well known that the rate limiting step in the 
utilization of glucose by muscle in the absence of insulin 
is the rate of transport of the sugar across the cell mem¬ 
brane whereas in the presence of insulin, the hexokinse step 
in the formation of G-6-P determines the overall rate. In 
our studies, basal glucose uptake was depressed by estrogen 
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treatment. Thus, it would appear that the muscle cell mem¬ 
brane becomes relatively less permeable to passive transfer 
of glucose by simple diffusion (the concentration of glucose 
used iri vitro was not great enough to saturate the process by 
mass action). In contrast, insulin-stimulated uptake was 
enhanced. It is possible that this represents an increase in 
activity in intracellular glucose utilization. There is some 
evidence from studies in rat uterine muscle to suggest such 
pathways of increased glucose utilization. Barker and 
Warren (5), using radioactively-labelled glucose, observed 
that 6 hours after the injection of estradiol in vivo the 
majority of estrogen stimulation of glucose utilization in 
the uterus occurs by increasing hexose monophosphate shunt 
activity; specifically, G6PD and 6PGD activities increase 
2-fold by 12 hours. Other studies have shown that an increase 
in uterine glycogen can be detected 1-2 hours after estrogen 
administration (92,164). 
Effects have also been observed on glucose transport in 
this system. Roskoski and Steiner (148) have shown that 
estrogen administration (single dose of 1 ug) increases the 
rate of 3-o-methyl-D-glucose transport into uterine cells 
in vitro. This finding is interesting in that it demon¬ 
strates increased uptake of a non-insulin-dependent sugar 
while the present investigation showed that glucose uptake 
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in the non-insulin treated diaphragm was depressed by estro¬ 
gen treatment. Aside from the obvious discrepancies in the 
biological models*, this may be related to the duration of 
estradiol administration. Their study also showed that estra¬ 
diol had no effect in vitro, a finding that complements our 
demonstration of the lack of in vitro effect of estradiol on 
insulin-dependent glucose uptake. The action on uterine 
muscle appeared after 1 hour indicating that the increase is 
not due to a primary physio-chemical interaction of the hor¬ 
mone with the sugar transport system in the membrane. 
This may help us understand the interaction of hormones 
whose sites of action are believed to be different -- that is, 
while insulin is believed to promote membrane transport of 
glucose and stimulate glycogenesis in muscle cells, estradiol 
is thought to act on specific nuclear receptors to activate 
the transcription of new mRNA with subsequent alterations of 
intracellular metabolism. 
Our studies failed to demonstrate an effect of in vitro 
treatment of diaphragm muscle with estradiol for up to 75 
minutes at supranormal concentrations. Taken by itself, this 
*The tissue specificity of estradiol has been studied with 
respect to receptor sites ifhich bind estrogen. Jensen et 
al. (93) have shown that rat diaphragm muscle does not 
accumulate the hormone under physiological circumstances as 
well as uterine muscle does. This may represent a quanti¬ 
tative rather than qualitative difference and, although, 
fewer in number, estrogen receptors are present in skeletal 
muscle (Dr. A. Eisenfeld, personal communication). 
, 
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fact does not tell us very much. There is some evidence that 
the effects of estrogen on uterine muscle can be manifested in 
as early as 60 minutes (92). On the other hand, the skeletal 
muscle preparation may be less sensitive than other specific 
target organs for estradiol; hence, more prolonged exposure 
to estrogen might be needed to detect any effects on glucose 
uptake. Indeed, in uterine muscle which has a high affinity 
for estrogen, the effects on glycogen synthesis are not seen 
until 1 to 2 hours after administration. We were successful, 
however, in demonstrating significant alterations in the 
glucose uptake of the muscle in vitro when estrogen was 
administered for two weeks in vivo. When compared to 
vehicle-treated controls, the estrogen-treated hemi-diaphragms 
showed a 16% lower basal glucose uptake and a 22% higher 
insulin-stimulated uptake. 
The lack of an acute effect in tissues other than uteri 
would thus seem to be a quantitative matter. In our hands, 
diaphragm muscle could not be said to "not respond to estro¬ 
gens" (164). 
We need not hypothesize a direct effect of estrogen on 
glycogen formation in diaphragm muscle, howeverf Our results 
can be explained on the basis of the markedly increased insu¬ 
lin sensitivity of the hemi-diaphragm which we have demonstrated 
following estrogen treatment. In vivo, this 2 to 3 fold 
increase in the sensitivity of muscle to insulin would result 
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in synthesis and an increased pool of intracellular glycogen* 
When removed from the animal, muscle metabolism becomes de¬ 
pendent on intracellular energy stores. Thus, tissues from 
estrogen-treated animals, having a higher glycogen content, 
would have a decreased glucose need. This is especially true 
in the basal state in which muscle depends on fatty acid and 
ketone utilization for the greater part of its energy require¬ 
ments with glucose being taken up only for glycogen formation 
(45). A consequent decrease in basal glucose uptake would be 
expected, as we have found. 
In the insulin-stimulated experimental state, however, 
the opposite holds true. Estrogen-treated muscle, highly 
sensitive to insulin, took up more glucose than untreated 
muscle. Glycogen synthesis and hexose monophosphate shunt 
activity may account for this increased glucose utilization. 
We can only speculate'as to how estrogen induces increased 
insulin sensitivity. Binding sites have been demonstrated 
to exist in cell membranes for both insulin (33) and estrogen 
(93). Numbers of insulin receptors or their affinity may be 
altered by estrogen. Both steroid (182) and peptide (200,203) 
hormones have effects on intracellular 3', 5'-cyclic AMP, 
certainly a likely candidate as a point of interaction. In 
addition, S^vik (165) has demonstrated that puromycin inhibits 
14 
C -glucose incorporation into glycogen but has no effect 
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on glucose uptake. Thus, there may be a protein synthesis 
dependent (enzyme synthetic) step in the insulin-mediated 
formation of glycogen. Similarly, in isolated rat uterine 
muscle puromycin blocks the estrogen stimulation of glucose 
metabolism, including glycogen formation (92). There would 
thus appear to be several possible sites for this interaction 
to occur 

50 
II. Studies of women taking oral contraceptives 
Numerous reviews of this subject are available, for 
example, Elgee (44), Spellacy (167), Yen and Vela (215) and 
most recently. Beck (12). The reader is referred to these 
sources for a more comprehensive discussion. 
The earliest reports on impaired carbohydrate metabolism 
in women on oral contraceptive agents observed that blood 
sugars were elevated in fasting subjects and that some overtly 
diabetic glucose tolerance tests developed. In Waine's origi¬ 
nal report (202), 4 of 8 patients placed on Enovid (mestranol 
and norethynodrel) developed diabetic glucose tolerance tests. 
Similar experience was reported by others (24, 136, 174) with 
this agent and other combinations of these steroids for 
treatment periods ranging from 1 month to more than 8 years. 
Wynn and Doar (212) reported a large series of women taking 
various agents and found up to 3/4 of healthy women with 
abnormalities in their OGTT and 13% developing chemical 
diabetes. Variations in the agents used and in the prior 
metabolic status of the subjects made it impossible to draw 
any conclusions from these early studies. 
Deterioration of glucose tolerance in normal subjects 
taking estrogen alone has been reported. Goldman and 
Ovadia (71) found that IVGTT worsened significantly in post¬ 
menopausal and post-partum women receiving DES or conjugated 
estrogens (as Premarin) by ten days of therapy. Subjects 
. 
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who were prediabetic by history showed more marked effects. 
Pyorala et al. (141), in a prospective study comparing the 
effects of mestranol + norethisterone acetate and ethinyl 
estradiol + norethisterone acetate, found increases in the 
numbers of subjects with abnormal OGTT after 20 days' treat¬ 
ment that were larger for the first group. When women were 
treated with sequential agents, the glucose disappearance (k) 
values of the IVGT tests decreased significantly during ethinyl 
estradiol treatment with no change when megestrol acetate (a 
progestogen) was added. They concluded that the estrogenic 
component of the oral contraceptives was responsible for the 
carbohydrate intolerance but that there were differences 
between various estrogens in the degree of impairment 
caused. 
Dipaola et al. (40,41) compared mestranol with ethinyl 
estradiol and concluded that 50 ug per day of the latter had 
no effect on prednisone glucose tolerance tests but that 
mestranol at doses of 40-80 ug per day elevates glucose con¬ 
centrations during the test. However, their subjects were 
taking other agents concurrently (especially progestogens). 
Javier et al. (91) investigated the effects of mestranol 
(75 ug per day) in premenopausal women. They found that the 
deterioration in OGTT and cortisone glucose tolerance tests 
were not associated with increased plasma insulin levels 
after a glucose load nor with fasting hyperglycemia. 
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Beck (10) used estradio}., estriol and ethinyl estradiol 
daily for two weeks in Rhesus monkeys tested before and during 
treatment with IV glucose tolerance tests. He found no signi¬ 
ficant changes in the serum glucose disappearance rate or 
plasma insulin concentrations. However, exogenously-admini¬ 
stered insulin resulted in a more gradual development of hypo¬ 
glycemia indicative of a decreased sensitivity of the animals 
treated with estrogen. In contrast, mestranol produced a 
significant increase in plasma insulin response to glucose 
and a decreased sensitivity to exogenous insulin; glucose 
disappearance, however, was unchanged. 
In patients taking combination or sequential estrogen- 
progestogen agents the results are even more conflicting. 
In Gershberg et al.'s (65) study of 59 women on a com¬ 
bination of 5 mg norethynodrel and 75 ug mestranol, 10% had 
elevated fasting blood glucose concentrations as compared to 
the normal mean. In addition, 1 and 2-hour glucose concen¬ 
trations were raised after an oral glucose load in 20 and 50% 
of subjects, respectively. 
Posner et al. (139,140) have shown the same combination 
to significantly impair IVGTT over a 2-3 month period when 
compared to pretreatment control values. With continued 
treatment, these effects persisted for 18 months in those 
subjects who gave a history suspicious for diabetes but 
normal subjects tended to return to their pretreatment levels 
after this period of time. 
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Spellacy et al. (175), in a study conducted for 1 year, 
observed that the same combination (Enovid) increased the 
total serum glucose during IVGTT, but the largest changes 
were seen in subjects who were older, obese or prediabetic. 
Plasma insulin values showed significant elevations at 15 
minutes, 30 minutes, 1 and 2 hours after a glucose load but 
fasting insulin levels were unchanged. Of note is the fact 
that the oral glucose tolerance test, especially when preceded 
by glucocorticoid priming, was more frequently reported as 
abnormal in all these studies than the intravenous test (167).* 
*While not directly pertinent to the question of estrogen and 
carbohydrate tolerance, it would be useful to mention the 
studies using progestational agents since much of the work 
on birth control pills has been done with combination agents. 
Muggia et al. (125) and Benjamin and Casper (16) were the 
first to report impaired carbohydrate tolerance with medroxy¬ 
progesterone and 17 -hydroxyprogesterone treatment. The use 
of the former agent by Gershberg et al. (66) decreased glucose 
tolerance in potential diabetics and diabetics. 
Chlormadinone (Vermeulen et al. (199) and Beck (11)), ethyno- 
diol diacetate (Goldman and Eckerling(69) and megestrol acetate 
(Spellacy et al. (178)) did not significantly affect glucose 
tolerance in normal women but did impair glucose disappearance 
rates during IVGTT in diabetics. 
Beck (10) tested several progestogens in Rhesus monkeys and 
found that some of the synthetic agents (e.g., chlormadinone 
acetate) increased the sensitivity of the pancreatic islet 
cell to a hyperglycemic stimulus. 
The overall effects of the progestogens on carbohydrate 
tolerance seem to be secondary to the combined estrogen. 
j 

54 
Certainly, most of the changes in carbohydrate tolerance seen 
with estrogens are small in normal women (12). Deterioration 
seems to be related to age, parity, pre-existing or subclinical 
diabetes and a family history of diabetes. This fact may only 
be due to the insensitivity of the usual investigatory methods 
(i.e., glucose tolerance tests) but does represent what seems 
to be a widespread clinical observation. 
Thus, there is some evidence that combinations of 19- 
nortestosterone derivative progestins and mestranol impair 
carbohydrate tolerance in response to a glucose load (12). A 
few studies report fasting hyperinsulinemia, but the most 
frequent picture is mild elevation of glucose and insulin 
concentrations during the glucose tolerance tests after long¬ 
term treatment with oral contraceptive combinations. Our 
studies show that short-term estradiol treatment increases 
the sensitivity of skeletal muscle to insulin while decreasing 
glucose utilization in the basal state. This discrepancy may 
be due to the previously mentioned difficulty of detecting 
effects on muscle metabolism as part of the overall state of 
carbohydrate tolerance in the intact subject. The effects 
of the sex steroids on a host of systems (107) make it 
probable that a number of aspects of insulin metabolism could 
be affected, in addition to well-established (46,81) hepatic 
effects. Furthermore, the chronic nature of the treatment 
with oral contraceptives raises a new problem, that of 
growth hormone. 
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This subject is quite extensive and only brief mention 
will be made here. Houssay and Biasotti had shown in 1931 
that hypophysectomy improved the diabetes of pancreatectomized 
animals. In 1947, Krahl and Cori (103,104,131) reproduced 
these findings and also showed that while the isolated dia¬ 
phragms of diabetic rats take up less glucose than normal, 
hypophysectomy returns the uptake to normal. 
Recently, Hjalmarson (82) showed that growth hormone (GH) 
in vivo, and in vitro when combined with dexamethasone, caused 
a decreased sensitivity to insulin in diaphragm muscle. 
Daughaday and Kipnis (36) have reviewed the subject of 
insulin antagonism by growth hormone. The effect of GH is on 
glucose uptake by tissues and not on insulin secretion per se. 
In fact, there is some evidence to suggest that GH elevates 
pancreatic insulin content and islet cell volume (1), and 
that it may increase the sensitivity of beta cells to glucose 
stimulation (20). 
Frantz and Rabkin (61) were the first to show that estro¬ 
gen elevates the HGH concentrations in men and women. In 
pregnant rats, GH is elevated above the levels seen in non¬ 
pregnant female rats (159). 
There have been several reports of increased fasting GH 
levels in women on oral contraceptive agents. Yen and Vela 
(214) found that ethinyl estradiol and mestranol elevated 
ambulatory fasting HGH levels at the same time as increasing 
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plasma insulin concentrations. Spellacy has found similar 
elevations with Enovid after 3 months (176) and one year (170). 
In addition, an enhanced GI-I response to insulin-induced hypo¬ 
glycemia was found. In contrast. Yen and Vela (215) found 
that GH values return to normal baseline after 3 months of 
treatment and thus may not play a role in the altered carbo¬ 
hydrate metabolism seen with chronic contraceptive steroid 
use. 
Davidson and Holzman (37) observed that normal females 
on a combination of 50 ug mestranol and 1 mg norethindrone 
showed an impairment in the fall in glucose and an enhancement 
of GH response following tolbutamide. This was interpreted as 
secondary to the insulin antagonism induced by GH. 
There is a midcycle augmentation in GH response to 
arginine infusion coincident with the preovulatory burst in 
plasma estrogen in normal women. Clomiphere citrate blunts 
this arginine-induced GH response (40). 
Thus, at least some of the impairment in carbohydrate 
tolerance seen with synthetic estrogen administration may be 
a consequence of the elevations in GH. The long-term effects 
of GH on insulin sensitivity of tissues is not well esta¬ 
blished 
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Conclusions 
Our studies demonstrate that estradiol increases the 
sensitivity of diaphragm muscle to the action of insulin, 
probably by increasing glucose utilization. This supports 
the findings that estrogens have a protective effect on the 
development of diabetes following subtotal pancreatectomy. 
We did not show any increase in endogenous insulin secretion 
to account for increased glucose uptake; improved tolerance 
to carbohydrate is secondary to augmented uptake by peripheral 
tissues more sensitive to circulating insulin. Reviev; of the 
literature on oral contraceptives indicates that estrogen/ 
progestin combinations may be diabetogenic. However, syn¬ 
thetic steroids are implicated most frequently, and mestranol 
combined with a 19-nortestosterone-derived progestin seems to 
impair glucose tolerance by inducing insulin resistance. It 
is possible that prolonged treatment with these agents ele¬ 
vates concentrations of growth hormone which antagonizes 
insulin action. 
Our failure to show an effect on glucose uptake with 
in vitro administration of estradiol may have been related to 
the relative insensitivity of skeletal muscle to estrogen. 
However, our demonstration of highly significant effect with 
in vivo administration suggests that estrogen acts in some 
fashion to increase insulin sensitivity of muscle 2 to 3 
times above control. The decrease in basal glucose uptake 
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combined with an increase in insulin-mediated uptake suggests 
that either directly, or via increased insulin sensitivity, 
intra-cellular glycogen content is elevated during in vivo 
estrogen treatment. 
We can only speculate as to the site of interaction of 
these hormones but further studies are needed to clarify this 
problem. 

Appendices 
SS = sum of squares 
df = degrees of freedom (n-1) 
MS a mean square 
* = repeated measures factor used to test the effects of 
treatment 
Treatment = Variance between groups (control, -i-insulin, etc.) 
Treatment by animal = Interaction 
Animals = variance within groups 
The S.E.M. calculated for q-test using the following equation 
where (MSis the mean square of the interaction 

Appendix A 
Analysis of Variance Table for Glucose Uptake (Control Expt.) 
Source SS df MS F-test 
Treatment 28.497 3 9.499 135.644 
*Treatment by 
animal 1.891 27 0.070 
P 
<.001 
Animals 42.087 9 4.676 

Appendix 13 
Analysis of Variance Table for Glucose Uptake (In vitro 
Comparison of three groups; Control, 
insulin, insulin-festradiol 
Source 
Treatment 
*Treatment by 
animal 
SS df 
35.474 2 
9.381 44 
84.638 22 
MS F-test 
17.737 83.193 
0.213 
3.847 
estradiol) 
P 
< .001 
Animals 

Appendix C 
Analysis of Variance Table for Glucose Uptake (Iri vitro estradiol) 
Comparison of four groups; Control, 
insulin, insulin-i-estradiol ( 2 ) 
* N=15 
Source 
Treatment 
*Treatments by 
animal 
ss df MS F-test P 
25.819 3 8.606 40.996 < .001 
8.817 42 0.210 
91.334 14 6.524 Animals 

Appendix D 
Analysis of Variance Table for Glucose Uptake (Ethanol) Com 
parison of three groups: control, insulin and 
insulin plus ethanol. 
n«=10 
Source SS df MS F-test P 
Treatment 16.823 2 8.412 52.285 <.001 
*Treatments by 
animal 2.896 18 0.161 
Animals 32.528 9 3.584 
Table i 
Mean Glucose Uptake (-S.E.M.) by Quarterdiaphragms, Control, 
insulin, and insulin+ethanol 
Control (I) Insulin (II) Insulin-i-ethanol (III) 
4.16-0.31 5.79-0.36 5.69-0.40 
Table ii 
Significance of differences between the means for Ethanol 
Groups tested q Significance (p) 
I vs. II 12.90 < .05 
I vs. Ill 12.09 <.05 
II vs. Ill 0.82 NS 

Appendix E 
Analysis of Variance Table for Glucose Uptake (Preincubation) 
n=9 
Source_S3_df_MS_F-test_p 
Treatment 12.039 2 6.020 44.572 <.001 
*Treatment by 
animals 2.161 16 0.135 
Animals 10.944 8 1.368 

Appendix F 
Analysis of Variance Table for Glucose Uptake (Pretreatment 
with and without estradiol, treatment with and without insu¬ 
lin in two Groups of 19 rats). Repeated Measures Design. 
Source SS df MS F-test 
.P .... . 
Pretreatment 1.143 1 1.143 9.300 =0.005 
*Animals 4.424 36 0.123 
Treatment 87.527 1 87.527 4857.3 < .001 
Pretreatment by 
treatment 12.776 1 12.776 708.9 < .001 
♦Treatment by 
animal 0.649 36 0.018 
TOTAL 106.518 75 1.420 
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